Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
EClinicalMedicine – March 14, 2025
Source: OpenAlex
Summary
Individuals with Alcohol use disorder experienced a 70% reduction in heavy drinking days over 32 weeks, versus 40% in a control group, after psilocybin-assisted psychotherapy. This compelling finding from a randomized controlled trial of 93 participants highlights psilocybin's potential in Medicine. Administered by a psychotherapist, this clinical trial demonstrates a novel approach for relapse prevention in Psychiatry. Psychedelics and drug studies, exploring compounds from chemical synthesis and alkaloids, offer new avenues for alcohol treatment, paralleling Cannabis and Cannabinoid Research.
Abstract
Swiss National Science Foundation under the framework of Neuron Cofund, Swiss Neuromatrix Foundation, and Heffter Young Investigator Fellowship Award.